{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:33Z","timestamp":1793382993015,"version":"4.5.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2025,1,10]]},"abstract":"<jats:p>Introduction. Real-world data on bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited. Material and methods. We conducted an observational retrospective cohort study of treatment-naive (TN, n=315) and treatment-experienced (TE, n= 2356) people living with HIV prescribed BIC\/FTC\/TAF in Argentina from 10\/2019 to 12\/2021, with 24 and 48-week follow-up data analyzed for virological suppression, persistence, safety, and metabolic parameters. Patient-reported outcomes were assessed via across-sectional online survey. Results. Baseline characteristics: median age 45 years, 72.2% male, 99.6% Hispanic\/Latino ethnicity. Treatment per sistence at 48 weeks was 99.3% (TN) and 99.5% (TE). Virological suppression rates (&lt;200\/&lt;50 copies\/mL) at 24 weeks were 97.4\/88% (TN) and 99\/97% (TE). At 48 weeks were 100\/92% (TN) and 99\/97% (TE). In the TE group, triglycerides decreased with no other lipid changes. In TN, mild total\/LDL\/HDL cholesterol increases occurred. eGFR mildly decreased in both groups. The online survey (n=536) showed 91.5% reported no medication concerns. Median quality of life scores were 90 (TN) and 88 (TE). Most reported no self-care, activity, mobility, pain\/discomfort, or anxiety\/depression issues. Conclusions. BIC\/FTC\/TAF demonstrated high persistence, safety, virological efficacy, and favorable metabolic profile over 48 weeks. The cross-sectional survey indicated high treatment satisfaction and good quality of life in this cohort from Argentina.<\/jats:p>","DOI":"10.37201\/req\/080.2024","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:05:00Z","timestamp":1732086300000},"page":"40-47","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir\/emtricitabine\/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort"],"prefix":"10.37201","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8545-6132","authenticated-orcid":false,"given":"Diego","family":"Cecchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-449X","authenticated-orcid":false,"given":"Mart\u00edn","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2478-1542","authenticated-orcid":false,"given":"Mar\u00eda Soledad","family":"Seleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2665-7181","authenticated-orcid":false,"given":"Mar\u00eda Ver\u00f3nica","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1893-5444","authenticated-orcid":false,"given":"Gast\u00f3n","family":"Copertari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-2783","authenticated-orcid":false,"given":"Brenda","family":"Bacelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1887-0328","authenticated-orcid":false,"given":"Romina","family":"Mauas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0602-5175","authenticated-orcid":false,"given":"Edgardo","family":"Bottaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4399-2628","authenticated-orcid":false,"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"23328","published-online":{"date-parts":[[2024,11,20]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T15:40:05Z","timestamp":1736523605000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2024-november-20-2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,1,10]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/080.2024","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}